Yadav Rubi, Sharma Sunita
Maharishi Markandeshwar Institute of Physiotherapy and Rehabilitation, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, Haryana 133207, India.
Int J Ther Massage Bodywork. 2024 Dec 12;17(4):49-57. doi: 10.3822/ijtmb.v17i4.1041. eCollection 2024 Dec.
Myofascial trigger points are incredibly prevalent and are a painful aspect of almost everyone's life at some point. Myofascial trigger point pain can be excruciating and severely impair the quality of life. Therefore, in patients with neck pain caused by upper trapezius trigger, this current clinical trial will demonstrate the effectiveness of myofascial release therapy and positional release therapy in improving the level of pain, neck impairment, pain threshold, and standard of life.
A double-blinded randomized clinical trial will be conducted. Fifty-two participants with active myofascial trigger points in the upper trapezius muscle will be recruited based on selection criteria. They will be randomly allocated into group A (conservative treatment + myofascial release technique) or group B (conservative treatment + positional release technique). Both groups will receive the intervention three times a week for 2 weeks. The study will use the Numeric Pain Rating Scale, pressure algometer, Neck Disability Index, and a 36-Item Short-form Questionnaire as outcome measures.
This trial will help identify the effectiveness of the positional and myofascial release techniques in active upper trapezius muscle trigger points and their effect on physical parameters.
This trial has been prospectively registered at the Clinical Trials Registry-India (CTRI/2023/07/055126) on 12 July 2023.
肌筋膜触发点极为常见,几乎在每个人生命中的某个阶段都是令人痛苦的一个方面。肌筋膜触发点疼痛可能极其剧烈,严重损害生活质量。因此,在因上斜方肌触发点引起颈部疼痛的患者中,本次临床试验将证明肌筋膜松解疗法和位置释放疗法在改善疼痛程度、颈部功能障碍、疼痛阈值及生活水平方面的有效性。
将进行一项双盲随机临床试验。根据入选标准招募52名在上斜方肌有活动性肌筋膜触发点的参与者。他们将被随机分为A组(保守治疗+肌筋膜松解技术)或B组(保守治疗+位置释放技术)。两组均每周接受3次干预,为期2周。本研究将使用数字疼痛评分量表、压力痛觉计、颈部功能障碍指数和一份36项简短问卷作为疗效指标。
本试验将有助于确定位置释放技术和肌筋膜松解技术在上斜方肌活动性触发点方面的有效性及其对身体参数的影响。
本试验已于2023年7月12日在印度临床试验注册中心(CTRI/2023/07/055126)进行前瞻性注册。